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32 The Journal of Thoracic and Cardiobjectives: The benefits of statin therapy for patients with coronary artery disease
ave been well documented, including those occurring after coronary artery bypass
raft surgery. The purposes of this study were to assess statin prescription rates in
atients who have undergone coronary artery bypass graft surgery and to identify
he determinants of postoperative statin administration.
ethods: A retrospective cohort of 9284 Medicare patients aged 65 years or older
ho underwent coronary artery bypass graft surgery (1995–2004) was assembled by
sing linked hospital and pharmacy claims data. Rates of statin use after hospital
ischarge were calculated, and predictors of postoperative statin use were identified
y using generalized estimating equations.
esults: Overall, 35.9% of patients received statins within 90 days of coronary
rtery bypass graft surgery discharge. Use of statins within 90 days after coronary
rtery bypass graft surgery steadily improved during the study period, from 13.1%
n 1995 to 60.9% in 2004. Patient factors independently associated with an increase
n postoperative statin therapy included preoperative statin use (odds ratio, 7.69),
ater year of operation (odds ratio, 1.22 per additional year), and additional post-
perative medications (odds ratio, 1.16 per additional medication). Factors inde-
endently associated with a decrease in postoperative statin therapy included pe-
ipheral vascular disease (odds ratio, 0.60), diabetes mellitus (odds ratio, 0.67),
troke (odds ratio, 0.77), and older age (odds ratio, 0.96 per additional year).
urgeon and hospital characteristics were not independently associated with post-
perative statin use.
onclusions: Statins are considerably underused after coronary artery bypass graft
urgery, although recent prescription rates are increasing. Patterns of use do not
ppear to correlate with coronary artery disease risk. These findings highlight the
eed for targeted quality improvement initiatives to increase the rate of statin
dministration to this at-risk population.
lthough coronary artery bypass graft (CABG) surgery effectively treats
ischemic heart disease, the long-term results after CABG surgery are
compromised by the progression of atherosclerosis in native coronary
rteries and saphenous vein bypass grafts.1,2 Only 60% of vein grafts remain pat
0 years after surgical intervention, and 50% of those that are patent have clinically
mportant stenosis.1,2 Accordingly, patients after CABG surgery are at high ris
ubsequent ischemic events, including death, myocardial infarction, and strok1,2
Clinical trials have consistently demonstrated that statins reduce the risk of recurrent
ardiovascular events and improve survival in patients with coronary artery disease
CAD), including survival in patients after CABG surgery. 3-5 In the largest stud
nvolving patients after surgical revascularization, treatment with 40 to 80 mg of
ovastatin daily reduced low-density lipoprotein (LDL) cholesterol levels to less than
vascular Surgery ● October 2007
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CD00 mg/dL and significantly reduced the progression of post-
perative vein graft disease compared with moderate choles-
erol treatment with 2.5 to 5 mg of lovastatin daily.5
The American Heart Association/American College of
ardiology Secondary Prevention Clinical Guidelines6 and
he National Cholesterol Education Program Adult Treat-
ent Panel III Guidelines7,8 currently recommend treatmen
o achieve LDL levels of less than 100 mg/dL for patients
ith documented atherosclerotic vascular disease, including
atients after CABG surgery. Because less than 7% of
atients with atherosclerosis are able to achieve LDL levels
f less than 100 mg/dL with diet and exercise regime9,10
n the absence of severe contraindications, essentially all
atients after CABG surgery are candidates for long-term
ostoperative statin therapy.11 Whether patients undergoing
ABG surgery actually receive statins after the operation is
argely unknown. Therefore we sought to assess the rate of
tatin use among patients discharged from the hospital after
ABG surgery and to identify the determinants of statin use
n this population.
aterials and Methods
etting and Design
e assembled a retrospective cohort of Medicare patients who
nderwent CABG surgery by linking Medicare files to data from
he Pennsylvania Pharmaceutical Assistance Contract for the El-
erly (PACE) and the New Jersey Pharmaceutical Assistance to
he Aged and Disabled (PAAD) programs. Both PACE and PAAD
rovide prescription drug benefits to lower middle-income indi-
iduals aged 65 years or older whose yearly earnings are above the
hreshold to qualify them for Medicaid. Participants pay copay-
ents of between $5 and $10 per prescription without any deduct-
bles. The programs cover all medications that require a prescrip-
ion and do not restrict which medications can be prescribed (ie,
he programs do not use formularies, preferred drug lists, or prior
uthorization programs).
Data from PACE, PAAD, and Medicare were incorporated into
relational database consisting of data for all filled prescriptions,
rocedures, physician encounters, hospitalizations, long-term care
dmissions, and deaths for the patients in this cohort. These data
Abbreviations and Acronyms
CABG coronary artery bypass grafting
CAD  coronary artery disease
CI  confidence interval
GEE  generalized estimating equation
LDL  low-density lipoprotein
OR  odds ratio
PAAD  New Jersey Pharmaceutical Assistance to the
Aged and Disabled
PACE  Pennsylvania Pharmaceutical Assistance
Contract for the Elderlyources have been used extensively to study population-based p
The Journal of Thoracicealth outcomes.12,13 All traceable person-specific identifying fa-
ors were transformed into anonymous, coded study numbers to
rotect subjects’ privacy. This study was approved by the institu-
ional review board of the Brigham and Women’s Hospital.
ohort
e included patients who were discharged from the hospital
fter undergoing CABG surgery (International Classification of
iseases–Ninth Revision 36.1x or 36.2x) between January 1,
995, and December 31, 2004. We excluded patients who died
ithin 90 days after surgical intervention, patients who were not
ctive users of either drug benefit program, and patients who
eceived prescriptions for cerivastatin since this drug was with-
rawn from the market. The date of discharge from the hospital
fter CABG was considered as the index date for the study
nalysis.
tatin Use
e assessed statin prescription rates (ie, prescriptions that were
lled) in the 1-year period before CABG surgery, as well as within
0 days, 180 days, and 365 days after the CABG discharge date.
atients were classified into drug and dose categories based on
heir statin prescription data before and after surgical intervention.
High-intensity statins” were those that would be expected to
ecrease LDL cholesterol levels by greater than 40% (atorvastatin,
10 mg; lovastatin, 40 mg; rosuvastatin, 5 mg; simvastatin,
40 mg). All other statin drug-dose combinations were considered
low-intensity statins” (atorvastatin, 10 mg; lovastatin, 40 mg;
osuvastatin, 5 mg; simvastatin, ’40 mg; any dose of fluvastatin;
ny dose of pravastatin).8,14
atient Covariates
e determined patient comorbidities by searching physician ser-
ice claims and hospitalization records for relevant diagnostic
odes in the 1-year period before the index date. In this manner the
ollowing characteristics were identified: age at index date, year of
peration, sex, race, length of hospital stay, previous myocardial
nfarction or acute coronary syndrome, hypertension, diabetes mel-
itus, congestive heart failure, stroke, peripheral vascular disease,
revious CABG surgery, previous percutaneous coronary interven-
ion, chronic kidney disease, and chronic obstructive pulmonary
isease. We also determined the use of the following concurrent
edications in the 1-year period before and 90 days after CABG
urgery: angiotensin-converting enzyme inhibitors or angiotensin
I receptor blockers, -blockers, calcium-channel blockers, fi-
rates, diuretics, nitrates, digoxin, warfarin, and clopidogrel.
ospital and Surgeon Covariates
e identified the hospital and surgeon for each CABG procedure.
ospitals that were accredited with the Association of American
edical Colleges were classified as teaching hospitals. All other
ospitals were classified as nonteaching hospitals. We classified
he “operating surgeon” as the cardiac, cardiothoracic, or thoracic
urgeon who submitted a claim for CABG on the date of surgical
ntervention using Medicare Part B claims. Records containing
nvalid provider identification numbers were excluded from further
nalysis. If 2 or more surgeons were identified for an individual
atient, then we defined the most responsible surgeon as the
and Cardiovascular Surgery ● Volume 134, Number 4 933
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CDurgeon that submitted the most claims for that specific patient
fter surgical intervention. The annualized volume of Medicare
atients undergoing CABG surgery treated by each surgeon was
stimated by dividing the total number of Medicare patients un-
ergoing CABG surgery for each surgeon during the study time
eriod by the number of years that each surgeon treated 1 or more
atients. Surgeons were ranked in order of annualized volume and
ere then categorized into high-, medium-, and low-volume sur-
eon tertiles of equal size. The annual volume of the hospital from
hich each patient was discharged was determined in a similar
anner as for surgeon volume, and high-, medium-, and low-
olume hospital tertiles were subsequently created.
tatistical Analysis
ur primary outcome was the rate of statin prescriptions that were
lled within 90 days after CABG discharge. We compared statin
sers and nonusers using unpaired 2-sided Student t tests, Fisher
xact tests, or 2 trend tests, as appropriate. Independent predictors
f postoperative statin use within 90 days after CABG discharge
ere identified by using generalized estimating equations (GEEs)
ith clustering at the surgeon level. Factors of clinical relevance
hought to affect postoperative statin rates were incorporated into
he GEE analysis, including age, sex, race, year of operation,
umber of postoperative medications, peripheral vascular disease,
reoperative stroke, recent myocardial infarction or acute coronary
yndrome, hypertension, diabetes mellitus, preoperative statin use,
eaching hospital, hospital volume, and surgeon volume. Odds
atios (ORs) are presented with 95% confidence intervals (CIs). All
nalyses were performed with SAS version 8.2 software (SAS
nstitute, Cary, NC).
ensitivity Analysis
dditional analyses were performed for confirmatory purposes,
ncluding the use of interaction terms in the GEE analyses and the
emoval of patients from the cohort who required long-term care
fter surgical intervention. Other methods of categorization (in-
tead of tertiles) were used to further evaluate associations be-
ween surgeon and hospital volume and postoperative statin use.
esults
atient Cohort
ur cohort consisted of 9284 patients who underwent
ABG surgery between 1995 and 2004. The mean age of
he cohort was 75.7 5.5 years, and 64.3% of patients were
omen. Preoperatively, the incidence of diabetes mellitus
as 48.1%, the incidence of stroke was 15.7%, and the
ncidence of peripheral vascular disease was 6.0%. The
ajority of patients underwent CABG surgery at teaching
ospitals (77.3%), with 89.7% undergoing operations at
igh-volume hospitals and 80.5% undergoing operations by
igh-volume surgeons. The mean length of stay after CABG
urgery was 11.1  7.2 days.
tatin Prescription Rates
uring the 1-year period before CABG surgery, 37.3% of
atients received a statin prescription (low-intensity statins, d
34 The Journal of Thoracic and Cardiovascular Surgery ● Octo0.8%; high-intensity statins, 6.5%). In contrast, only
5.9% of patients undergoing CABG surgery were pre-
cribed statins within 90 days after the CABG procedure
low-intensity statins, 30.3%; high-intensity statins, 5.6%).
f the patients who received preoperative statin therapy,
nly 67.4% of these patients received postoperative statins.
tatin administration rates were low among all patient sub-
roups, including those with diabetes mellitus, cerebrovas-
ular disease, or peripheral vascular disease (statin rates of
7.5%, 33.1%, and 32.3%, respectively). In comparison with
tatin use, 57.3% of patients received -blockers after surgical
ntervention, 36.3% received angiotensin-converting enzyme
nhibitors or angiotensin II receptor blockers, 21.1% re-
eived calcium-channel blockers, 19.3% received digoxin,
7.8% received nitrates, 14.8% received warfarin, 8.0%
eceived clopidogrel, 5.0% received diuretics, and 1.6%
eceived fibrate therapy.
Statin prescription rates increased with duration of time
fter surgical intervention, from 35.9% to 42.0% to 48.1%
ithin 90, 180, and 365 days after CABG discharge, re-
pectively (Figure 1). Statin prescription rates also i
reased substantially with each additional year in the
tudy, with a low of 13.1% in 1995 to a maximum of
0.9% in 2004 (Figure 2). The most common statins 
fter surgical intervention included simvastatin (15.7%)
nd atorvastatin (12.7%). Fewer patients were prescribed
ravastatin (4.6%), lovastatin (2.0%), fluvastatin (0.9%),
nd rosuvastatin (0.1%).
redictors of Statin Use
able 1 describes the characteristics of the patients who
nd did not receive statins within 90 days after CABG
igure 1. Statin prescription rates before and after coronary
rtery bypass grafting (CABG) surgery. Prescription rates de-
reased slightly from before surgical intervention to 90 days after
urgical intervention but then steadily increased to 1 year after
ABG surgery.ischarge. Statin users were more likely to have received
ber 2007
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CDreoperative statins than nonusers (P  .0001). Postopera-
ive statin users were also more likely to have taken other
ardiac medications both before and after surgical interven-
ion (all P  .05). Although statin users were more likely to
e female and have diabetes mellitus, nonstatin users were
ore likely to be older, have longer hospital stays, and have
ther comorbidities (stroke, congestive heart failure, and
hronic obstructive pulmonary disease; all P  .05). Statin
sers were more likely to have had operations in recent
ears, although nonstatin users were more likely to have had
perations at teaching hospitals (P  .10) and at high-
olume hospitals (P  .01).
After adjusting for patient-, surgeon-, and hospital-related
haracteristics, the strongest predictor of postoperative statin
herapy was preoperative statin use (OR, 7.69; 95% CI,
.81– 8.68; P  .0001; Table 2). Later year of operat
OR, 1.22 per additional year; 95% CI, 1.19–1.25; P 
0001) and additional postoperative medications (OR, 1.16
er additional medication; 95% CI, 1.15–1.18; P  .0001)
lso independently predicted postoperative statin use. Fac-
ors associated with a reduction in postoperative statin use
ncluded a history of peripheral vascular disease (OR, 0.60;
5% CI, 0.48–0.75; P  .0001), diabetes mellitus (OR,
.67; 95% CI, 0.59–0.75; P  .0001), preoperative stroke
OR, 0.77; 95% CI, 0.67–0.90; P  .0006), and older age
OR, 0.96 per additional year; 95% CI, 0.95–0.97; P 
0001). Surgeon and hospital characteristics were not inde-
endently associated with postoperative statin use. Sensi-
ivity analyses yielded nearly identical results to those
igure 2. Statin prescription rates within 90 days after coronary
rtery bypass grafting (CABG) surgery stratified by year of oper-
tion. Statin prescription rates steadily increased each year of
he study.resented. c
The Journal of Thoracic aABLE 1. Baseline characteristics for patients treated
ith and without statins 90 days after CABG discharge
haracteristic
Nonstatin users
(n  7121)
Statin users
(n  3474)
emographics
Age, mean  SD 75.9  5.5 75.2  5.4*
Female sex, % 62.4 67.8*
White race, % 92.6 91.8
omorbid conditions, %
Prior myocardial infarction 16.0 13.4*
Congestive heart failure 52.6 47.4*
Stroke 16.4 14.4*
Peripheral vascular disease 6.4 5.4
Hypertension 87.6 91.9*
Diabetes 46.9 50.2*
Chronic kidney disease 27.2 27.2
Chronic obstructive pulmonary
disease
32.5 28.8*
Previous CABG 0.1 0.4*
Previous stent/PTCA 9.0 9.9
reoperative medication use, %
Prior statin 19.0 70.0*
ACE inhibitor or angiotensin II
receptor blocker
35.7 51.8*
Clopidogrel 8.2 19.4*
-Blocker 47.8 71.6*
Calcium-channel blocker 43.8 50.5*
Digoxin 13.8 16.8*
Diuretics 6.5 10.1*
Fibrate 3.4 4.0
Nitrates 47.6 59.5*
Warfarin 10.2 11.7*
ostoperative medication use, %
ACE inhibitor or angiotensin II
receptor blocker
29.4 48.6*
Clopidogrel 4.1 14.7*
-Blocker 46.0 77.2*
Calcium-channel blocker 18.8 25.0*
Digoxin 17.8 21.9*
Diuretics 3.7 7.3*
Fibrate 1.6 1.5
Nitrates 16.4 20.4*
Warfarin 14.3 15.6
ospital characteristics
Teaching hospital, % 77.9 76.4
nnual volume of hospital, %
High (54 patients/y) 90.2 88.8
Medium (3-53 patients/y) 9.2 10.8*
Low (2 patients/y) 0.7 0.4
nnual volume of surgeon, %
High (20 patients/y) 80.5 80.4
Medium (3-19 patients/y) 17.1 17.5
Low (3 patients/y) 2.3 2.1
ength of stay, mean  SD 11.8  7.2 10.1  5.0*
ABG, Coronary artery bypass grafting; SD, standard deviation; PTCA,
ercutaneous transluminal coronary angioplasty; ACE, angiotensin-
onverting enzyme. *P  .05.
nd Cardiovascular Surgery ● Volume 134, Number 4 935
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CDiscussion
linical trials have consistently demonstrated that statins
educe the risk of recurrent cardiovascular events and im-
rove survival across a wide range of cholesterol levels in
atients with CAD.3 The benefits of statin treatment appe
o be applicable to men and women, as well as to older and
ounger patients.3 As one of the safest classes of drugs 
eveloped,15 statins are recommended as preventive thera
or patients with CAD, even after surgical revasculariza-
ion.7,16 Given the weight of the evidence and the fact
tatins have been shown to reduce saphenous vein graft
isease,4,5,17 in the absence of serious contraindicatio
ffectively all patients after CABG surgery should be pre-
cribed long-term statin therapy.6-8 In contrast, we observe
hat (1) overall, only 37.3% of patients received statin
herapy before CABG surgery, and even fewer patients
35.9%) were prescribed statins within 90 days postopera-
ively; (2) although rates of statin prescriptions have in-
reased substantially over time, they still remain subopti-
al; and (3) patients with risk factors for future vascular
vents, such as diabetes mellitus and history of stroke, were
he least likely to receive statins.
As the largest study to date to have evaluated medical
herapy after CABG surgery, the results of this research
ABLE 2. Multivariable predictors of postoperative statin
se
haracteristic
Adjusted odds ratio
(95% confidence interval)
ncreased statin use
Preoperative statin use 7.69 (6.81–8.68)
Year of operation (per additional
year)
1.22 (1.19–1.25)
Postoperative medications (per
additional medication)
1.16 (1.15–1.18)
ecreased statin use
Peripheral vascular disease 0.60 (0.48–0.75)
Diabetes mellitus 0.67 (0.59–0.75)
Stroke 0.77 (0.67–0.90)
Patient age (per additional year) 0.96 (0.95–0.97)
onsignificant factors
Male sex 1.05 (0.95–1.16)
White race 0.99 (0.82–1.20)
Prior myocardial infarction 0.98 (0.84–1.13)
Hypertension 1.00 (0.83–1.20)
Teaching hospital 1.01 (0.86–1.19)
Medium-volume vs low-volume
hospital
1.49 (0.78–2.87)
High-volume vs low-volume hospital 1.52 (0.79–2.91)
Medium-volume vs low-volume
surgeon
0.93 (0.62–1.38)
High-volume vs low-volume surgeon 0.98 (0.67–1.44)onfirm those of smaller cohort studies that have docu- t
36 The Journal of Thoracic and Cardiovascular Surgery ● Octot
ented low statin prescription rates after CABG sur-
ery.18,19 Most recently, in a study of 320 patients un-
oing CABG surgery, the use of antilipid agents was 55% at
dmission, 57% at CABG discharge, and 76% at 12 months
fter surgical intervention.20 Likewise, in a study of eviden
ased preventive therapies in 31,750 Duke University patients,
ewby and colleagues21 reported the consistent use of lip
owering therapy in only 44% of patients with CAD (treated
ith medical, percutaneous, or surgical therapy). Similar to
he current study, Newby and colleagues21 also reported tha
he use of lipid-lowering agents increased over time, with
3% of patients taking lipid-lowering therapy in 2002 com-
ared with approximately 25% in 1995. The results our
ohort and that from Duke21 both identified older age as
redictor of lower statin use, despite the fact that the elderly
erive more absolute benefit from statins as a consequence
f their high baseline risk of cardiovascular disease.3,22
In addition to advanced age, patients with other cardiac
isk factors paradoxically received less preventive statin
herapy after surgical intervention compared with that re-
eived by patients without these risk factors. A history of
eripheral vascular disease, diabetes mellitus, and stroke
ere all independently associated with a reduction in post-
perative statin prescription rates. Patients with these risk
actors could benefit the most from statin therapy.3,21 This
nding is analogous to the results reported by Lee and
ssociates23 regarding the underuse of angiotensin-conve-
ng enzyme inhibitors and -blockers in patients with heart
ailure at the greatest risk of death. Physician belief that
atients with comorbidities will experience less benefit and
reater harm from statin therapy is one potential explanation
or this treatment-risk paradox. Alternatively, physicians
ight be less attentive to preventive therapy when caring
or patients with multiple concurrent conditions, or they
ight be less inclined to prescribe medications to patients
hought unlikely to adhere to treatment.23,24
The strongest factor associated with the administration of
ostoperative statin therapy in our cohort was the use of
reoperative statins. As a consequence, encouraging appro-
riate preoperative statin use might be an effective strategy
o increase postoperative use. Moreover, preoperative statin
se reduces the incidence of adverse cardiovascular events
fter CABG syurgery.25,26 Still, only 67% of patients w
eceived preoperative statins were prescribed statins after
urgical intervention in this study, suggesting that preven-
ive statin therapy is being forgotten or disregarded after
ABG surgery.
Overall, too few patients are being prescribed statins
fter CABG surgery, and this study highlights the need for
argeted quality improvement initiatives focusing on the
rescription habits of cardiac surgeons and cardiologists.
everal researchers have explored approaches to improvinghese treatment gaps in cardiovascular care and preven-
ber 2007
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CDion.22,27 Audit with feedback on performance is one -
ortant method that can be used to achieve this goal among
atients after CABG surgery and should be explored fur-
her.20 Moreover, recent randomized controlled trials ha
emonstrated that, compared with usual care, the addition of
lectronic information systems (electronic medical record
eminders and automated voice message reminders) or the
se of integrated team care models (pharmacy team out-
each groups and transition coaches) might improve medi-
ation administration and therapeutic monitoring after hos-
ital discharge.28,29
Through the use of a large database and robust statistical
ethods, we believe that our study provides the best current
valuation of statin administration after CABG surgery.
owever, our results should be interpreted in the context of
everal limitations.
First, this research focused specifically on elderly pa-
ients enrolled in Medicare and the PACE and PAAD pre-
cription drug benefit plans. Because the average age of
atients undergoing CABG surgery in this cohort was 75.7
ears and 64.7% of patients were female, our results might
ot be generalizable to patients with other demographic or
linical characteristics.
Second, the administrative data used does not contain
etailed clinical information, such as cholesterol levels, or
he reasons for physicians’ prescription choices. For exam-
le, statins might have preferentially been prescribed to
atients with higher baseline cholesterol levels. Moreover, it
s possible that patients who filled their statin prescriptions
n this study might not have actually ingested the medica-
ions. That said, it is generally agreed that the rate of
rescriptions being filled by patients well approximates
heir actual consumption.30
Finally, it is impossible to differentiate patient noncom-
liance in filling a prescription from physician nonprescrip-
ion in our data.
In summary, much progress has been made in the eval-
ation of preventive therapies, and yet many patients do not
eceive the medical therapies that can improve their out-
omes. This study illustrates that statins are considerably
nderused after CABG surgery. However, their use has
ncreased in recent years. These findings highlight the need
or targeted quality improvement initiatives to further in-
rease the rate of statin administration to this at-risk
opulation.
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